Andor Glaudemans is nuclear medicine specialist and deputy head at the department of Nuclear Medicine and Molecular Imaging of the University Medical Center in Groningen. He is president of the Dutch Society of Nuclear Medicine, and co-chair of the Infection and Inflammation Committee of the European Association of Nuclear Medicine.

His expert areas, both in patient care and in research, are (1) infections, (2) inflammatory diseases, and (3) tumor immunology. He is appointed as Professor in Multimodality Imaging of Infections and Infectious Diseases at the University of Groningen, (co-)author of > 300 peer-reviewed articles, supervisor of > 20 PhD students, editor of several Springer textbooks, member of several Editoral Boards, and involved in the development of many European guidelines and PET procedural recommendations for infections and inflammatory diseases. His goal for DECIVISE is to create a strong Dutch consortium with all the key players in the field to strengthen the whole chain in Nuclear Medicine of the Netherlands, all for better diagnostic and therapeutic possibilities for the patient.

Frank Nijsen is Associate Professor at the Department of Medical Imaging department at Radboud university medical center Radboudumc). His research group focuses on experimental interventional nuclear medicine and is part of the research group NucMed and he leads the research group MAGIC (Minimally Invasive Image-Guided Intervention Center). Furthermore he is an active member of the Dosimetry Core Unit (DCU) and spokesperson for the Research Program "Advanced Imaging”.

Frank studied biology and medical biology at the University of Amsterdam. He performed his PhD research on "Radioactive holmium-loaded poly(L-lactic acid) microspheres for treatment of liver metastases" at the Departments of Pharmacy of the University of Utrecht and Nuclear Medicine, University Medical Center Utrecht (UMCU). In 2011, he was asked by UMCU as the leading person in the valorization of the holmium microspheres for malignancies: GMP production, scale up, quality Assurance, market plan, co-founding the start-up company Quirem Medical (2013) and CE-mark (2015). Within Quirem Frank became Chief Scientific Officer. The valorization circle was successfully completed on July 15th, 2020 with the acquisition of Quirem by Terumo.

In his role in the Radboudumc, his group (ca. 10 PhD candidates, 2 Post-docs and 1 technologist) is investigating (real-time) image-guided radioembolization and new applications for radioactive internal treatment with particles of tumors (brain, head & neck, pancreas, prostate and lung). His group also focuses on optimizing the techniques to obtain a better patient outcome; by investigating new microspheres, new and smart administration techniques, fully image-guided treatments (Emeritus project, Sloth project, Deliver project), radiobiology (UNRANU project) & dosimetry and flow dynamics (ULTIMO project) of these microspheres. Within his research there is a close collaboration with the medical specialists (nuclear physicians, interventional radiologists, oncologists, radiotherapists and immunologists), Institutes of Technology, Pharmacy, patient associations and companies. The research that is performed fits into a strong bench-to-bedside-to-community approach within translational research.

Sandra Heskamp studied Biomedical Sciences at the Radboud University of Nijmegen. In 2009, she graduated in two master’s: Epidemiology and Biostatistics and Human Pathobiology. That same year she started her PhD project Molecular Imaging of Receptor Tyrosine Kinases in Cancer, a collaborative project between the department of Nuclear Medicine and Medical Oncology. During her PhD she also worked as a visiting researcher at the Technical University Munich to study the potential of alpha-emitting radionuclides for cancer treatment. In June 2014, she obtained her PhD and started working as a post-doc at the department of Medical Imaging at the Radboudumc. In 2021 she was appointed as full professor and currently she leads a research group focusing on nuclear imaging and therapy in immuno-oncology.

Sandra received several personal grants and awards, including a Veni and Vidi, and she is principal investigator of several collaborative grants. She is president of the Dutch Society of Clinical Radiochemistry (NKRV), co-chair of the Oncoimmunology & Therapy group of the European Society of Molecular Imaging (ESMI), board member of Dutch journal for Nuclear Medicine (TvNG) and chair of the Radboudumc Technology Center Imaging.

Info coming soon

Bart Cornelissen holds appointments at the University Medical Center Groningen's Department of Nuclear Medicine and Molecular Imaging, and the University of Oxford's Departments of Oncology and the Nuffield Department of Surgery.

Bart trained in analytical chemistry and radiochemistry in Belgium, where he obtained his PhD in radiopharmaceutical sciences from the University of Ghent and spent several years at the University of Toronto as a post-doctoral fellow before joining the University of Oxford.

Bart's research programme focuses on the development of radiolabelled compounds for imaging and therapy in oncology, and the understanding of the radiobiology of radionuclide therapy.

Riemer Slart is full professor “Multimodality Cardiovascular Imaging” at the University of Groningen (RUG) since 2019 and part-time clinical full professor “Translational Molecular Imaging” at the University of Twente (UT), Enschede, the Netherlands since 2014.

Since 2001 he is permanent medical staff member as nuclear medicine physician of the Department of Nuclear Medicine & Molecular Imaging of the Medical Imaging Center at the UMCG. After a 2 year cross-over training he is registered now as well in cardiac radiology (CT & CMR). He is member of the Amyloidosis Center of Expertise and the Vasculitis Expertise Center of the Netherlands.

From 2014-2021 he was board member and secretary of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee and currently he is member of the EANM Guideline Council. In 2016 he became member of the imaging working group large vessel vasculitis of the EULAR and in 2018 Chair of the working group Cardiovascular Imaging in infections and inflammation (4Is), a collaboration between the EANM and the EACVI/ESC. He is medical director of Molecular Imaging of the Center of Medical Imaging North-East Netherlands since 2018.

Riemer Slart is teacher in cardiovascular imaging at the European School of Molecular Imaging & Therapy (ESMIT) of the EANM, at the EULVIC for rheumatologists  and other teaching & training projects. He organized internships for the IAEA at his department in Groningen, to train technologists, physicians and clinical physicists in nuclear cardiology imaging, and is the founder of EURO-LEARN web platform. The European Increasing Awareness of Nuclear Scintigraphy in Cardiac Amyloidosis with support of the EANM/ESMIT and EACVI. At the University of Twente he is involved in several technical medicine projects, including AI, teaching in Technical Medicine curriculum, and bridging the clinic with technical needs & developments.

He is author of > 420 peer-reviewed publications in mainly Q1 international journals, contributed in 30 book chapters/book, and is Associate Editor & Editorial board-member of 6 scientific journals. He serves as a peer reviewer for more than a dozen scientific journals. He is involved in several international recommendations/guidelines in molecular imaging and initiator and conductor of several imaging research trials and international oriented.

Erik de Blois (1981, Zeist) started his MLO training at Zadkine Rotterdam and graduated in 2001 in biotechnology. He then studied part-time at HLO at the HvU Utrecht and graduated in 2005. In the following year he continued his part-time study in pharmaceutical sciences at the University of Utrecht in the direction of "Drug innovation". He graduated in 2009, after which he started his PhD program part-time at Erasmus MC. In 2014 he successfully defended his thesis: Radiochemical Aspect of receptor Scintigraphy: labeling with radiometals, optimization and radiochemical purity and obtained his doctorate. In the meantime, he started in 2002 as a research analyst in the radiochemistry group at the Nuclear Medicine department at Erasmus MC. After obtaining his Master's degree, his position changed to Clinical Radiochemist and is responsible for the clinical implementation of new non-registered radiopharmaceuticals. Since 2021 he is also Head of Quality Control and responsible for the release of radiopharmaceuticals made in-house. Within his position he contributed to the implementation of various (therapeutic) radiopharmaceuticals, including the first registered drug Lu-177 labeled DOTA-TATE (Lutathera®). In 2018 he became board member (treasurer) of the Dutch Society of clinical radiochemistry (NKRV) and in 2022 also board member of the Dutch Society of nuclear medicine (NVNG).

Julie Nonnekens received her MSc in Biotechnology at Wageningen University in 2009. She obtained her PhD in cancer biology with the focus on DNA repair mechanisms at the University of Toulouse (France) in 2013. Following, she was a postdoc at the Hubrecht Institute working on ribosome biogenesis in cancer and longevity. In 2014 Julie joined the Erasmus MC Departments of Radiology & Nuclear Medicine and Molecular Genetics and is now Associate Professor. The research of her group bridges the interests of both departments in the field of DNA damage repair mechanisms and nuclear medicine to study the radiation biology of targeted radionuclide anticancer treatment in order to ultimately optimize treatment regimens.

Julie has received several (young investigator) awards and is principal investigator on various research grants including the prestigious ERC starting grant. She is president of the Netherlands Society for Radiobiology and co-founder of the European working group on Radiobiology of Molecular Radionuclide Therapy.

Jeroen van Moorselaar is professor and chairman of the Department of Urology at the Amsterdam University Medical Center. He studied medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. In 1991 he obtained his PhD degree on ‘Cytokine Therapy in Experimental Urological Cancer’.

He was certified as urologist in June 1997. From that time he has worked in the University Hospitals in Nijmegen and Utrecht and since September 2005 in Amsterdam. He is member of various national and international organizations. He is chairman of the Dutch working party on prostate cancer guidelines and is founding member of the Dutch UroOncology Study group. Since May 2007 he is board member of the European School of Urology. Furthermore he is president of the European Board of Urology. In 2023 he became member of the Board of SONCOS (Dutch multidisciplinary oncological platform).

He is an active researcher in the field of urological oncology focused on bladder and prostate cancer.